Lactobacillus reuteri and applications

A technology of Lactobacillus reuteri and antibacterial drugs, applied in the field of microorganisms, can solve problems such as poor effect of enteritis, and achieve the effects of good development and application prospects, easy operation, and strong resistance to stress.

Pending Publication Date: 2017-03-22
天益健康科学研究院(镇江)有限公司
View PDF3 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, Existing Probiotics Are Ineffective in Treating Enteritis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lactobacillus reuteri and applications
  • Lactobacillus reuteri and applications
  • Lactobacillus reuteri and applications

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] The isolation of embodiment 1 bacterial strain

[0038] 1. Strains, medium and culture conditions

[0039] (1) Bacterial source

[0040] Feces of healthy soldiers from a military region in China.

[0041] (2) culture medium

[0042] Plate medium: 1000mL distilled water, 10g peptone, 20g glucose, 9g yeast powder, 5g sodium acetate, 2g dipotassium hydrogen phosphate, 2g triammonium citrate, 0.5g cysteine, 0.2g magnesium sulfate, 0.05g manganese sulfate, Tween 1ml, agar powder 15-20g, pH5.5-6.5.

[0043] 2. Isolation and identification of strains

[0044] (1) Isolation of strains

[0045] Take an appropriate amount of fresh feces from the pre-sterilized glove box and place them in a sterile test tube filled with sterile medium, vortex and mix well;

[0046] Take the feces solution that was fully shaken and vortexed as the stock solution, and make a ten-fold gradient dilution to a suitable gradient, take 100 μl and evenly spread it on the MRS+0.05% cysteine ​​solid pl...

Embodiment 2

[0066] (1) Functional evaluation of strains

[0067] A. Determination of growth curve and pH value of each monitoring point

[0068] 1. mark

[0069] Take 11 large sterile test tubes and mark the incubation time with a marker pen, namely 0, 2, 4, 6, 8, and 24 hours.

[0070] 2. Vaccination

[0071] Use 5mL sterile pipettes to draw 2.5mL TR02 overnight culture solution (cultured for 8-16h) into the Erlenmeyer flask filled with 50mL MRS+0.05% cysteine ​​culture solution, mix well and take 5mL of the mixed solution into the above-mentioned Labeled 11 large sterile test tubes.

[0072] 3. Cultivate

[0073] Place the inoculated test tubes in a 37°C incubator for static culture, and culture them for 0, 2, 4, 6, 8, and 24 hours respectively. Take out the test tubes marked with the corresponding time and store them in the refrigerator immediately. optical density value.

[0074] 4. Nephelometric assay

[0075] Use uninoculated MRS+0.05% cysteine ​​medium as blank control, choo...

Embodiment 3

[0104] Embodiment 3 in vivo experiments

[0105] 1. Induction and treatment of colitis

[0106] C57BL / 6 type mice (1-7 days) were fed with a solution containing 2.5% DSS (molecular weight 36-50KDa) to induce colitis model mice; the control group was fed water. In the following 10 days, water, lactic acid bacteria (embedded 0.9*10 9 , 1.2*10 9 , 2.4*10 9 , unembedded 2.4*10 9 ) and sulfasalazine pyridine (0.5g / kg).

[0107] Weigh the body weight every day, observe the consistency of the feces and whether there is blood in the feces and the anus of the mice. Disease activity index (DAI) was calculated. In short, calculations are performed with the following parameters:

[0108] a) Diarrhea (0 = normal, 2 = loose stools, 4 = watery diarrhea);

[0109] b) Blood gallbladder (0 points = no bleeding, 2, slight bleeding, 4 points, heavy bleeding).

[0110] On day 10 after induction of colitis, animals were sacrificed, colons were removed, and colon tissue pieces were prepared...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses lactobacillus reuteri. The classification name of lactobacillus reuteri is lactobacillus reuteri TR02, the lactobacillus reuteri TR02 is preserved in the China Center for Type Culture Collection (CCTCC), and is assigned with the accession number of CCTCC No. M 2016546, and the preservation date is Oct 10, 2016.The invention further discloses applications of lactobacillus reuteri in preparing medicines for treating gastrointestinal diseases.

Description

technical field [0001] The invention belongs to the technical field of microorganisms, and in particular relates to a lactobacillus reuteri and its application in the preparation of medicines for treating gastrointestinal diseases. Background technique [0002] Ulcerative colitis (UC), cryptitis, and Rohn's disease are major types of inflammatory bowel disease (IBD), which is characterized by chronic inflammation in the intestine. Clinical signs are diarrhea, abdominal pain, occasional rectal bleeding, weight loss, tiredness, and sometimes fever. Although it can occur at any age, IBD is most common in adolescents and young adults, so these individuals may suffer from delayed development and stunted growth. Statistics show that the annual prevalence of UC in the United States is 200 / 100,000 people, and the cost of treating UC is about 100 to 150 million US dollars. As of 2012, the total number of UC patients is 2.5 times that of 2000, and the recurrence rate is 72%; In recen...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N1/20A61K35/747A61P31/04A61P1/00C12R1/225
CPCA61K2035/115C12R2001/225C12N1/205
Inventor 李珮铷贾长生边高瑞
Owner 天益健康科学研究院(镇江)有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap